DemeRx is a subsidiary of atai that aims to develop ibogaine for Opioid Use Disorder.
“DemeRx is a clinical stage pharmaceutical development company advancing two lead drug candidates as medication-assisted therapies for opioid addiction. Our natural product lead drug – lbogaine – is an indole alkaloid from equatorial Africa, which blocks opioid withdrawal symptoms and drug cravings, helping drug dependent patients to transition to sobriety. The Company has developed a robust IP portfolio around Noribogaine, the principal active metabolite of lbogaine.”
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates